Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dropouts due to adverse events · adults (aged 18‐85)
Comparison 3: MAOIs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (low certainty).
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD
Comparison 7: MAOIs may leads to higher global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (low certainty).
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD
1 finding from 1 review
Clinical Global Impressions scale change item (CGI‐I): no. of responders (long term) Post‐treatment: 1‐4 months · adults with SAnD
It is very uncertain whether comparison 7: MAOIs changes clinical Global Impressions scale change item (CGI‐I):no. of… compared with placebo (very low certainty).
1 finding from 1 review
Failure to respond at endpoint (6‐12 weeks) · adults with panic disorder
SSRIs showed no clear difference in failure to respond compared with MAOIs (moderate certainty).
1 finding from 1 review
Leaving the study early · adults with panic disorder
SSRIs showed no clear difference in total number of dropouts compared with MAOIs (low certainty).
1 finding from 1 review
Failure to remit at endpoint · adults with panic disorder
SSRIs showed no clear difference in failure to remit compared with MAOIs (moderate certainty).
1 finding from 1 review
panic symptoms · adults with panic disorder
1 finding from 1 review
Withdrawals due to adverse events · adults with panic disorder
SSRIs showed no clear difference in number of dropouts due to adverse events compared with MAOIs (low certainty).
1 finding from 1 review